Review
Biochemistry & Molecular Biology
Olesja Rogoza, Kaspars Megnis, Marija Kudrjavceva, Aija Gerina-Berzina, Vita Rovite
Summary: Somatostatin receptors play a crucial role in the treatment of neuroendocrine tumors, delaying tumor progression and regulating hormone overproduction. The expression level of SSTRs has predictive value in therapeutic response and patient survival rate. Future research will focus on other epigenetic regulators affecting somatostatin signaling and combination therapy strategies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Endocrinology & Metabolism
Leonidas Nikolaos Diamantopoulos, Faidon-Marios Laskaratos, Markos Kalligeros, Ruchir Shah, Shaunak Navalkissoor, Gopinath Gnanasegaran, Jamie Banks, Jack Smith, Benjamin Jacobs, Michail Galanopoulos, Dalvinder Mandair, Martyn Caplin, Christos Toumpanakis
Summary: In this study, above-label doses of somatostatin analogs showed promising antiproliferative effects in patients with inoperable/metastatic gastroenteropancreatic neuroendocrine tumors. Symptomatic improvement and disease control were observed in some patients after 3-weekly administration, with certain factors associated with inferior or better progression-free survival. Higher doses of SSAs may be beneficial as a bridge to other treatments, particularly for patients with specific tumor characteristics.
NEUROENDOCRINOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Sofie Eline Tollefsen, Ole Solheim, Patricia Mjones, Sverre Helge Torp
Summary: Meningioma is a common brain tumor without approved specific drugs. This study aims to compile the current insights of somatostatin analogs for treating patients with meningioma. A systematic search was conducted, and 17 eligible studies were evaluated. Although the efficacy of somatostatin analogs remains unclear, some studies suggest that they may be a last-option treatment for severely ill-patients. However, a controlled study or randomized clinical trial is needed to establish their efficacy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Endocrinology & Metabolism
Sabrina Chiloiro, Antonella Giampietro, Federica Mirra, Federico Donfrancesco, Tommaso Tartaglione, Pier Paolo Mattogno, Flavia Angelini, Lauretti Liverana, Marco Gessi, Anile Carmelo, Guido Rindi, Andrea Giustina, Maria Fleseriu, Alfredo Pontecorvi, Laura De Marinis, Antonio Bianchi
Summary: The study investigated predictors of response to Pegvisomant and Pasireotide LAR in acromegaly patients, finding that factors such as tumor extension, Ki67-Li levels, and IGF-I levels may impact treatment efficacy.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2021)
Review
Endocrinology & Metabolism
A. Faggiano
Summary: This review summarizes the relevant data on long-acting SSAs in NET patients, showing that long-acting SSAs are an effective and safe initial therapy for well differentiated NET, providing long-term tumor growth and symptom control in selected patients.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
(2023)
Article
Gastroenterology & Hepatology
Winson Y. Cheung, Callahan LaForty, Anna Liovas, Heather McKechnie, Jonathan M. Loree
Summary: This real-world observational study provides valuable insights into the use of somatostatin analogs in clinical settings and may help guide treatment selection.
Review
Medicine, General & Internal
Alexandru Dan Popescu, Mara Carsote, Ana Valea, Andreea Gabriela Nicola, Ionela Teodora Dascalu, Tiberiu Tirca, Jaqueline Abdul-Razzak, Mihaela Jana Tuculina
Summary: Acromegaly-related sub/infertility is associated with suboptimal disease control, hyperprolactinemia, hypogonadotropic hypogonadism, and glucose profile anomalies. This review explores the impact of acromegaly on pregnancy outcomes and discusses management strategies. The level of disease control, family history of diabetes, and body mass index are important predictors of maternal complications. Pharmacotherapy has been shown to be safe and effective in improving pregnancy outcomes.
Article
Oncology
Yoshitaka Honma, Masafumi Ikeda, Susumu Hijioka, Shigemi Matsumoto, Tetsuhide Ito, Taku Aoki, Junji Furuse
Summary: Systemic therapy options for gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) vary in effectiveness based on the primary site. Japanese experts have proposed optimal first-line treatment strategies for unresectable GEP-NET using somatostatin analogues (SSA) and everolimus, taking into consideration tumor aggressiveness and prognosis prediction based on hepatic tumor load and Ki-67 labeling index. Additionally, the origin of the tumor in the midgut should be considered when determining the treatment strategy.
INVESTIGATIONAL NEW DRUGS
(2023)
Article
Oncology
Francesca Corti, Maria Pia Brizzi, Vito Amoroso, Dario Giuffrida, Francesco Panzuto, Davide Campana, Natalie Prinzi, Massimo Milione, Tommaso Cascella, Carlo Spreafico, Giovanni Randon, Simone Oldani, Rita Leporati, Giulia Scotto, Iolanda Pulice, Benedetta Lombardi Stocchetti, Luca Porcu, Jorgelina Coppa, Maria Di Bartolomeo, Filippo de Braud, Sara Pusceddu
Summary: The LOLA trial aims to evaluate the safety and activity of cabozantinib combined with lanreotide in WD NETs, providing potential new treatment options for patients with these rare tumors.
Article
Surgery
Catherine G. Tran, Aaron T. Scott, Guiying Li, Scott K. Sherman, Po Hien Ear, James R. Howe
Summary: Metastatic pancreatic neuroendocrine tumors have lower expression of somatostatin compared to primary tumors, and knocking down somatostatin can increase cell growth and metabolic activity. This phenomenon may be attributed to increased activation of Akt.
Article
Endocrinology & Metabolism
Sabrina Chiloiro, Antonio Bianchi, Antonella Giampietro, Alfredo Pontecorvi, Gerald Raverot, Laura De Marinis
Summary: This review provides an overview of the second-line therapies for acromegaly, summarizing the evidence on clinical, molecular, and morphological aspects that can predict the response to these treatments and advocating for a patient-tailored therapeutic approach in clinical practice.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Medicine, Research & Experimental
Brooke Harrow, Francis Fagnani, Camille Nevoret, Xuan-Mai Truong-Thanh, Marie de Zelicourt, Louis de Mestier
Summary: This retrospective cohort study compared the use of lanreotide autogel (LAN) and octreotide long-acting release (OCT) in patients with neuroendocrine tumors (NETs) using a French claims database. The results showed that patients receiving LAN had longer treatment duration, lower treatment discontinuation rate, and fewer incidences of dose above recommended level and rescue medication use.
ADVANCES IN THERAPY
(2022)
Article
Oncology
Elettra Merola, Teresa Alonso Gordoa, Panpan Zhang, Taymeyah Al-Toubah, Eleonora Pelle, Agnieszka Kolasinska-Cwikla, Wouter Zandee, Faidon Laskaratos, Louis De Mestier, Angela Lamarca, Jorge Hernando, Jaroslaw Cwikla, Jonathan Strosberg, Wouter De Herder, Martin Caplin, Mauro Cives, Rachel van Leeuwaarde
Summary: Long-acting somatostatin analogs demonstrate antiproliferative activity in pancreatic NETs with Ki-67 >= 10%, particularly in G2 tumors and when hepatic tumor load is <= 25%.
Article
Endocrinology & Metabolism
Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Angela Lamarca, Jorge Barriuso, Angel Castano, Marta Benavent, Vicente Alonso, Maria del Carmen Riesco, Teresa Alonso-Gordoa, Ana Custodio, Manuel Sanchez Canovas, Jorge Hernando, Carlos Lopez, Adelaida La Casta, Ana Fernandez Montes, Monica Marazuela, Guillermo Crespo, Jose Angel Diaz, Eduardo Feliciangeli, Javier Gallego, Marta Llanos, Angel Segura, Felip Vilardell, Juan Carlos Percovich, Enrique Grande, Jaume Capdevila, Juan Valle, Rocio Garcia-Carbonero
Summary: This study evaluated the external validity of RCTs examining SSAs in the real world, as well as the main effect-modifying factors. The results indicate that both octreotide LAR and lanreotide autogel had a similar effect on PFS, making them valid alternatives in patients with well-differentiated, metastatic GEP-NENs.
NEUROENDOCRINOLOGY
(2022)
Review
Medicine, Research & Experimental
David Cella, Jennifer Evans, Marion Feuilly, Sebastian Neggers, Dirk Van Genechten, Jackie Herman, Mohid S. Khan
Summary: Based on a systematic literature review, LAN was favored over OCT in the treatment of acromegaly and NETs, with technical problems and pain during injections being the most influential factors in treatment experience.
ADVANCES IN THERAPY
(2021)
Article
Endocrinology & Metabolism
W. Vena, A. Pizzocaro, G. Maida, M. Amer, A. Voza, A. Di Pasquale, F. Reggiani, M. Ciccarelli, C. Fedeli, D. Santi, E. Lavezzi, A. G. Lania, G. Mazziotti
Summary: Hypogonadism is common in male patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Low testosterone (T) levels are associated with unfavorable outcomes of COVID-19, and further prospective studies are needed to evaluate the long-term outcomes of hypogonadism related to COVID-19 and the clinical impact of T replacement during and after acute illness.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
(2022)
Review
Endocrinology & Metabolism
G. Corona, W. Vena, A. Pizzocaro, V. A. Giagulli, D. Francomano, G. Rastrelli, G. Mazziotti, A. Aversa, A. M. Isidori, R. Pivonello, L. Vignozzi, E. Mannucci, M. Maggi, A. Ferlin
Summary: Testosterone replacement therapy (TRT) can inhibit bone resorption and increase bone mass, especially at the lumbar spine level. The effects are more prominent with longer duration of treatment and higher prevalence of diabetes in patients.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
(2022)
Article
Endocrinology & Metabolism
E. Vitali, E. Palagano, M. L. Schiavone, G. Mantovani, C. Sobacchi, G. Mazziotti, A. Lania
Summary: This study provides the first evidence of the direct action of OCT on osteoblasts, which may have clinically relevant implications for the management of skeletal health in subjects with acromegaly and metastatic NETs.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
(2022)
Article
Medicine, General & Internal
Cristiano Sconza, Francesco Coletta, Nicola Magarelli, Maria Cristina D'Agostino, Colin Gerard Egan, Berardo Di Matteo, Stefano Respizzi, Gherardo Mazziotti
Summary: Bone marrow edema syndrome is a disabling condition without a defined treatment. In this case report, a patient was treated conservatively and showed significant improvement in symptoms.
SAGE OPEN MEDICAL CASE REPORTS
(2022)
Article
Endocrinology & Metabolism
Anda Mihaela Naciu, Gaia Tabacco, John P. Bilezikian, Assunta Santonati, Daniela Bosco, Giosue Giordano Incognito, Gianluigi Gaspa, Silvia Manfrini, Alberto Falchetti, Pierpaolo Trimboli, Gherardo Mazziotti, Nicola Napoli, Gianfranco Sanson, Roberto Cesareo, Fabio Vescini, Andrea Palermo
Summary: This study evaluated the therapeutic advantage of calcium citrate (Ca-Cit) compared to calcium carbonate (CaCO3) in hypoparathyroidism, and found that Ca-Cit may have a potential beneficial effect on reducing the risk of nephrolithiasis. Additionally, Ca-Cit was associated with less constipation symptoms compared to CaCO3.
JOURNAL OF BONE AND MINERAL RESEARCH
(2022)
Review
Endocrinology & Metabolism
Gherardo Mazziotti, Andrea G. Lania, Ernesto Canalis
Summary: This review highlights the pathophysiological, clinical and therapeutic aspects of skeletal fragility associated with perturbations in the GH-IGF1 axis, such as GH deficiency, anorexia nervosa, ageing and acromegaly. These perturbations cause changes in bone remodelling, increase the risk of fractures, and can affect the effectiveness of treatment.
NATURE REVIEWS ENDOCRINOLOGY
(2022)
Review
Gastroenterology & Hepatology
Nicola Pugliese, Ivan Arcari, Alessio Aghemo, Andrea G. Lania, Ana Lleo, Gherardo Mazziotti
Summary: Primary biliary cholangitis and primary sclerosing cholangitis are the most common cholestatic liver diseases in adults, characterized by an immune pathogenesis. Osteoporosis and sarcopenia are frequently seen complications of CLD and have significant impacts on patient's health and quality of life. The underlying mechanisms and optimal treatments for these complications in CLD are still unclear and require further research and expert guidance.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Endocrinology & Metabolism
Piero Ferolla, Alfredo Berruti, Francesca Spada, Maria Pia Brizzi, Toni Ibrahim, Riccardo Marconcini, Dario Giuffrida, Vito Amoroso, Anna La Salvia, Vanja Vaccaro, Antongiulio Faggiano, Annamaria Colao, Marco Volante, Simona Ghizzoni, Paola Mazzanti, Aude Houchard, Nicola Fazio
Summary: This study showed that the combination therapy of LAN/TMZ has promising efficacy in progressive T-NETs, and was well tolerated.
NEUROENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
W. Vena, F. Carrone, A. Delbarba, O. Akpojiyovbi, L. C. Pezzaioli, P. Facondo, C. Cappelli, L. Leonardi, L. Balzarini, D. Farina, A. Pizzocaro, A. G. Lania, G. Mazziotti, A. Ferlin
Summary: This study evaluated the associations between body composition parameters, vertebral fractures, and trabecular bone score in adult males with Klinefelter syndrome. The results suggest that body composition may influence bone quality and the risk of vertebral fractures in individuals with Klinefelter syndrome.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
(2023)
Editorial Material
Oncology
Alfredo Berruti, Vito Amoroso, Nicola Fazio
Article
Endocrinology & Metabolism
M. F. Birtolo, W. Vena, A. Pizzocaro, E. Lavezzi, A. Brunetti, S. Jaafar, N. Betella, A. C. Bossi, G. Mazziotti, A. G. Lania
Summary: This study investigated the relationship between serum testosterone levels and outcomes of COVID-19 in a large cohort of female patients. The results showed that high testosterone levels were associated with higher inflammatory markers and worse course of COVID-19, although this association disappeared after correcting for inflammatory parameters.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
(2023)
Review
Endocrinology & Metabolism
L. Cianferotti, C. Cipriani, S. Corbetta, G. Corona, G. Defeudis, A. G. Lania, C. Messina, N. Napoli, G. Mazziotti
Summary: Endocrine diseases can lead to osteoporosis and fractures, but traditional bone density measurement methods may not accurately capture skeletal alterations caused by endocrine disorders. Therefore, it is important to use new techniques to assess bone quality for the diagnosis and prediction of skeletal fragility and fracture risk.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Martina Sollini, Margarita Kirienko, Luca di Tommaso, Cristiano Pini, Fabrizia Gelardi, Salvatore Ariano, Andrea Gerardo Lania, Gherardo Mazziotti, Giuseppe Mercante, Arturo Chiti
Summary: This study investigated the potential role of Prostate Specific Membrane Antigen (PSMA) in thyroid carcinoma (TC) and found that PSMA expression and 2-[F-18]fluoro-2-deoxy-D-glucose ([F-18]FDG) uptake on PET/CT can serve as complementary biomarkers for TC outcome prediction.
Article
Endocrinology & Metabolism
Maria Francesca Birtolo, Simone Antonini, Andrea G. Lania, Gherardo Mazziotti
Summary: Skeletal fragility and vertebral fractures are common complications of growth hormone hypersecretion in acromegalic subjects. The coexistence of spine arthropathy further negatively impacts the quality of life for these patients. Managing these complications can be challenging even after controlling the disease biochemically. This article provides an analysis of the pathophysiological links between vertebral fractures and spine arthropathy in active and controlled acromegaly, as well as the diagnostic and therapeutic aspects of managing acromegalic osteo-arthropathy.
Article
Endocrinology & Metabolism
Gherardo Mazziotti, Rebecca Pedersini, Walter Vena, Deborah Cosentini, Flaminia Carrone, Stella Pigni, Edda L. Simoncini, Rosalba Torrisi, Alberto Zambelli, Davide Farina, Luca Balzarini, Andrea G. Lania, Alfredo Berruti
Summary: This prospective study aimed to investigate the real-life effectiveness of bone-active drugs on the risk of vertebral fractures induced by aromatase inhibitors (AIs) in breast cancer patients. The results suggest that in real-world clinical practice, denosumab and zoledronate can significantly reduce the risk of vertebral fractures in breast cancer patients using AIs.
CALCIFIED TISSUE INTERNATIONAL
(2022)